[Paspertin (Metoclopramide) as a cause of dystonic-hyperkinetic syndromes in children].
D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D001712:Biperiden / Q000627:therapeutic use; D002648:Child; D003975:Diazepam / Q000627:therapeutic use; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced / Q000188:drug therapy; D007223:Infant; D008297:Male; D008614:Meperidine / Q000627:therapeutic use; D009069:Movement Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010634:Phenobarbital / Q000627:therapeutic use
D000577:Amides; D001565:Benzoates; D001712:Biperiden; D008614:Meperidine; D003975:Diazepam; D010634:Phenobarbital
Paspertin (Metoclopramid) als Ursache des dyston-hyperkinetischen Syndroms bei Kindern.